The Effect of Intravitreal Bevacizumab Injection in Eales' Disease
Journal of the Korean Ophthalmological Society
; : 1595-1599, 2009.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-173414
Responsible library:
WPRO
ABSTRACT
PURPOSE:
To report on 2 cases of Eales' disease that were successfully regressed with laser photocoagulation and intravitreal bevacizumab (Avastin; Genetech, Inc, San Francisco, California, USA) injection. CASESUMMARY:
Two male patients (30 years and, 40 years of age,) with a history of recurrent vitreous hemorrhage were diagnosed with Eales' disease. The 2 patients had peripheral retina neovascularization and active phlebitis in fundus fluorescein angiography. No other findings were observed in their eyes in the general examination. Scatter laser photocoagulation and intravitreal bevacizumab injection were performed. After 1 month follow-up, neovascularization completely regressed. There was no complication or recurrent vitreous hemorrhage at the 1 year follow up.CONCLUSIONS:
Intravitreal bevacizumab injection, as combination treatment of laser photocoagulation, may be helpful in the regression of neovascularization due to Eales' disease.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Phlebitis
/
Retina
/
Vitreous Hemorrhage
/
Fluorescein Angiography
/
California
/
Follow-Up Studies
/
San Francisco
/
Eye
/
Antibodies, Monoclonal, Humanized
/
Bevacizumab
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
/
Male
Country/Region as subject:
North America
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2009
Document type:
Article